Regeneron Pharmaceuticals, Inc.
REGN
$574.47
$46.698.85%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 16.63% | 11.61% | 16.62% | 0.53% | -7.77% |
| Total Depreciation and Amortization | 13.80% | 14.70% | 15.05% | 14.65% | 18.82% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -133.15% | -54.29% | -159.55% | -89.83% | -38.97% |
| Change in Net Operating Assets | -980.76% | -557.07% | -269.85% | -474.60% | 112.78% |
| Cash from Operations | -16.58% | -3.78% | -18.70% | -14.10% | 10.70% |
| Capital Expenditure | -26.25% | -5.19% | -30.40% | -26.61% | -7.63% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | 69.95% | 69.95% | 82.78% | -- | 76.16% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 118.28% | 28.85% | 51.50% | 45.30% | -167.95% |
| Cash from Investing | 97.12% | 22.51% | 42.03% | 34.54% | -100.28% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -37.14% | 27.92% | 37.66% | 33.33% | -9.49% |
| Repurchase of Common Stock | -46.34% | -23.74% | -12.26% | 6.38% | 4.04% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -134.90% | -22.93% | 5.06% | 32.73% | -1.74% |
| Foreign Exchange rate Adjustments | 144.44% | -75.00% | 133.33% | -100.00% | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 136.63% | 34.80% | 88.96% | 98.53% | -331.57% |